Condition (MeSH)
Choroiditis
ClinicalTrials.gov lists 21 trials for Choroiditis or a narrower condition beneath it. National Eye Institute (NEI) has the most among industry and government lead sponsors, with 2.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
2 of the 21 trials are tagged with Choroiditis itself; the rest are tagged with a narrower condition beneath it.
When did Choroiditis trials start? (15)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 3
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2024 | 1 |
| 2023 | 2 |
| 2022 | 2 |
| 2020 | 2 |
| 2018 | 2 |
| 2013 | 1 |
| 2011 | 1 |
| 2010 | 3 |
| 2008 | 1 |
| 2007 | 1 |
Showing 10 of 15 earlier years.
No forecast is made for this condition: it averages 1.0 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 1 trial still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Choroiditis trials in? (6)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 2 | 2 |
| Phase 2/3 | 1 |
| Phase 3 | 3 |
| Phase 4 | 1 |
| Not applicable | 3 |
| Observational | 11 |
How many Choroiditis trials are recruiting? (4)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Recruiting | 2 |
| Completed | 11 |
| Withdrawn | 3 |
| Unknown status | 5 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Choroiditis trials? (3)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| National Eye Institute (NEI) | 2 |
| Novartis Pharmaceuticals | 1 |
| TScan Therapeutics, Inc. | 1 |
Interventions as named in the registry (15)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Bevacizumab 1 | 3 |
| pyrimethamine-sulfadiazine + prednisolone | 1 |
| Intravitreal Injection of Bevacizumab (1.25 mg/0.05ml) | 1 |
| Bevacizumab, Dexamethasone, Verteporfin Photodynamic Therapy | 1 |
| Triamcinolone Acetonide alone | 1 |
Showing 5 of 15 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Choroiditis trials report? (5)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Hypokalaemia | 1 | 1 |
| Pyelonephritis | 1 | 1 |
| Tibia fracture | 1 | 1 |
| Urinary tract infection | 1 | 1 |
| Uterine cancer | 1 | 1 |
Which publications cover Choroiditis? (9)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Efficacy and safety of abatacept to treat active birdshot uveitis: a prospective open label interventional proof-of-concept trial. | The British journal of ophthalmology | 2024 | Yes |
| Risk Factors for Developing Choroidal Neovascular Membrane and Visual Loss in Punctate Inner Choroidopathy. | Ophthalmology | 2018 | Yes |
| The Features of Inflammation Factors Concentrations in Aqueous Humor of Polypoidal Choroidal Vasculopathy. | PloS one | 2016 | Yes |
| Non-cytomegalovirus ocular opportunistic infections in patients with acquired immunodeficiency syndrome. | American journal of ophthalmology | 2013 | Yes |
| Three-year visual and anatomic results of administrating intravitreal bevacizumab in inflammatory ocular neovascularization. | Canadian journal of ophthalmology. Journal canadien d'ophtalmologie | 2012 | Yes |
Showing 5 of 9 publications.
Prevalence (1)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| Posterior uveitis | Point prevalence | Unknown | Worldwide | Not stated | Unspecified |
Sub-conditions in MeSH (3)
MeSH descendants one level down with at least one trial, most trials first.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: rare-disease identity.